ArticleJournal of molecular histology2025
Attenuation of brucine action on DMBA/TPA-induced skin cancer by PI3K/Akt/mTOR signaling.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Method to Study Skin Cancer: Two-Stage Chemically Induced Carcinogenesis in Mouse Skin.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Revealing key biomarkers and molecular mechanisms associated with di(2-ethylhexyl) phthalate in skin cancer.Frontiers in molecular biosciences · 2026Article
- Multimodal analysis reveals potential association of CDH13 with endothelial cells and its overexpression in hepatocellular carcinoma.European journal of medical research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cancer (SC) contributes to 40% of global tumor incidences. Brucine (BRU) is an anticancer alkaloid that is reported to have chemopreventive activities on the SC model. Hence, this study hypothesizes to explore the potential molecular mechanism of BRU on 7,12-dimethylbenz (a)anthracene/12-O-Tetradecanoyl Phorbol-13-Acetate (DMBA/TPA)-stimulated skin carcinogenesis via apoptotic signalling pathway. ICR male mice were separated into 4 groups: Normal control (NC); SC model (DMBA/TPA); DMBA/TPA + BRU (25 mg/kg bw); and DMBA/TPA + BRU (50 mg/kg bw). We assessed the change in body weight, thymus index, morphology changes in skin, liver, and renal tissue histopathology analysis, inflammatory and apoptotic markers by ELISA method, apoptotic, autophagy, and cell proliferation markers by RT-PCR methods. Current findings showed that BRU (25 and 50 mg/kg bw) + DMBA/TPA-stimulated mice increased body weight and suppressed inflammation in a dose-dependent manner. BRU-administered SC model, tissue, and blood sample pro-inflammatory markers IL-4, IL-18, and IL-1β decreased, but anti-inflammatory marker IL-10 increased. Furthermore, BRU treatment normalized the apoptotic mRNA expressions Bad, Bax, Bcl-xl, and Bcl-2 expression in tissue and blood samples in a dose-dependent manner. BRU altered the histopathological changes from hepatic, skin, and renal damage. Furthermore, BRU treatment elevated the autophagy-correlated mRNA expressions, including Microtubule-associated protein 1 light chain 3-LC3, LC3-II, and Beclin1, while reducing LC3-I and p62 levels. BRU induces apoptosis, inhibits cell proliferation and maintains tissue damage. We recommended that BRU potent chemotherapeutic drug for the recovery of Skin cancer. in the future, protein levels identification needs to be studied at the next levels of animal or experimental models.
Indexed as
Identifiers
40616731What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.